StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Receives Positive CHMP Opinion for Marketing Odefsey as HIV-1 Treatment
April 29, 2016 8:11 AM
On 28 April 2016 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM
Gilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
April 29, 2016 6:50 AM
Form 8-K GILEAD SCIENCES INC For: Apr 28
April 28, 2016 4:13 PM
Gilead Sciences (GILD) Raises Quarterly Dividend 9.3% to $0.47; 1.9% Yield
April 28, 2016 4:07 PM
Gilead Sciences Announces Second Quarter 2016 Dividend
April 28, 2016 4:06 PM
